These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17119036)

  • 61. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.
    Artigalás O; Vanni T; Hutz MH; Ashton-Prolla P; Schwartz IV
    BMC Med; 2015 Jun; 13():139. PubMed ID: 26067721
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The impact of CYP19A1 variants and haplotypes on breast cancer risk, clinicopathological features and prognosis.
    Alwan AM; Afzaljavan F; Tavakol Afshari J; Homaei Shandiz F; Barati Bagherabad M; Vahednia E; Kheradmand N; Pasdar A
    Mol Genet Genomic Med; 2021 Jul; 9(7):e1705. PubMed ID: 34014013
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women.
    Tao MH; Cai Q; Zhang ZF; Xu WH; Kataoka N; Wen W; Xiang YB; Zheng W; Shu XO
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):943-9. PubMed ID: 17507620
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: the Breast Cancer Health Disparities Study.
    Boone SD; Baumgartner KB; Baumgartner RN; Connor AE; Pinkston CM; Rai SN; Riley EC; Hines LM; Giuliano AR; John EM; Stern MC; Torres-Mejía G; Wolff RK; Slattery ML
    Cancer Causes Control; 2014 Nov; 25(11):1461-71. PubMed ID: 25088806
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CD24 polymorphisms in breast cancer: impact on prognosis and risk.
    Buck K; Hug S; Seibold P; Ferschke I; Altevogt P; Sohn C; Schneeweiss A; Burwinkel B; Jäger D; Flesch-Janys D; Chang-Claude J; Marmé F
    Breast Cancer Res Treat; 2013 Feb; 137(3):927-37. PubMed ID: 23314606
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
    Ferraldeschi R; Arnedos M; Hadfield KD; A'Hern R; Drury S; Wardley A; Howell A; Evans DG; Roberts SA; Smith I; Newman WG; Dowsett M
    Breast Cancer Res Treat; 2012 Jun; 133(3):1191-8. PubMed ID: 22418701
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CYP19A1 genetic polymorphisms may be associated with obesity-related phenotypes in Chinese women.
    Long JR; Shu XO; Cai Q; Wen W; Kataoka N; Gao YT; Zheng W
    Int J Obes (Lond); 2007 Mar; 31(3):418-23. PubMed ID: 16894362
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.
    Friesenhengst A; Pribitzer-Winner T; Miedl H; Pröstling K; Schreiber M
    Horm Cancer; 2018 Apr; 9(2):128-138. PubMed ID: 29363090
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss.
    Yip L; Zaloumis S; Irwin D; Severi G; Hopper J; Giles G; Harrap S; Sinclair R; Ellis J
    Br J Dermatol; 2009 Aug; 161(2):289-94. PubMed ID: 19438456
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
    Napoli N; Rastelli A; Ma C; Colleluori G; Vattikuti S; Armamento-Villareal R
    Pharmacogenet Genomics; 2015 Aug; 25(8):377-81. PubMed ID: 26049585
    [TBL] [Abstract][Full Text] [Related]  

  • 71. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk.
    Haiman CA; Hankinson SE; Spiegelman D; Brown M; Hunter DJ
    Cancer Epidemiol Biomarkers Prev; 2002 Feb; 11(2):215-6. PubMed ID: 11867511
    [No Abstract]   [Full Text] [Related]  

  • 72. Neurokinin 1 receptor gene polymorphism might be correlated with recurrence rates in endometriosis.
    Renner SP; Ekici AB; Maihöfner C; Oppelt P; Thiel FC; Schrauder M; Uenluehan N; Bani MR; Strissel PL; Strick R; Beckmann MW; Fasching PA
    Gynecol Endocrinol; 2009 Nov; 25(11):726-33. PubMed ID: 19903051
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Human aromatase: gene resequencing and functional genomics.
    Ma CX; Adjei AA; Salavaggione OE; Coronel J; Pelleymounter L; Wang L; Eckloff BW; Schaid D; Wieben ED; Adjei AA; Weinshilboum RM
    Cancer Res; 2005 Dec; 65(23):11071-82. PubMed ID: 16322257
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.
    Olson JE; Ingle JN; Ma CX; Pelleymounter LL; Schaid DJ; Pankratz VS; Vierkant RA; Fredericksen ZS; Wu Y; Couch FJ; Vachon CM; Sellers TA; Weinshilboum RM
    Breast Cancer Res Treat; 2007 Apr; 102(2):237-47. PubMed ID: 17004113
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women.
    Cai H; Shu XO; Egan KM; Cai Q; Long JR; Gao YT; Zheng W
    Pharmacogenet Genomics; 2008 Aug; 18(8):657-64. PubMed ID: 18622258
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genetic polymorphisms and haplotype of hormone-related genes are associated with the risk of breast cancer in Chinese women.
    Pan Z; Fu Z; Song Q; Cao W; Cheng W; Xu X
    Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323034
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Interaction of soy food and tea consumption with CYP19A1 genetic polymorphisms in the development of endometrial cancer.
    Xu WH; Dai Q; Xiang YB; Long JR; Ruan ZX; Cheng JR; Zheng W; Shu XO
    Am J Epidemiol; 2007 Dec; 166(12):1420-30. PubMed ID: 17827443
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes.
    Vymetalkova V; Soucek P; Kunicka T; Jiraskova K; Brynychova V; Pardini B; Novosadova V; Polivkova Z; Kubackova K; Kozevnikovova R; Ambrus M; Vodickova L; Naccarati A; Vodicka P
    PLoS One; 2015; 10(7):e0134463. PubMed ID: 26226484
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population.
    Lee SJ; Kim WY; Choi JY; Lee SS; Shin JG
    J Hum Genet; 2010 Mar; 55(3):189-93. PubMed ID: 20186154
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
    Tang L; Platek ME; Yao S; Till C; Goodman PJ; Tangen CM; Wu Y; Platz EA; Neuhouser ML; Stanczyk FZ; Reichardt JKV; Santella RM; Hsing A; Figg WD; Lippman SM; Thompson IM; Ambrosone CB
    Carcinogenesis; 2018 Feb; 39(2):125-133. PubMed ID: 29228205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.